Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Pomalidomide + Talquetamab-tgvs |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pomalidomide | Pomalyst | CC-4047 | Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov). | |
Talquetamab-tgvs | Talvey | JNJ64407564|JNJ 64407564|JNJ-64407564 | CD3 Antibody 97 | Talvey (talquetamab-tgvs) is a bispecific antibody that targets CD3 and GPRC5D, potentially resulting in increased immune response against GPRC5D-expressing tumor cells (PMID: 32040549). Talvey (talquetamab-tgvs) is FDA-approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06208150 | Phase III | Dexamethasone + Elotuzumab + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide Talquetamab-tgvs + Teclistamab Pomalidomide + Talquetamab-tgvs Dexamethasone | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 15 |
NCT05050097 | Phase I | Lenalidomide + Talquetamab-tgvs Daratumumab + Lenalidomide + Talquetamab-tgvs Pomalidomide + Talquetamab-tgvs Carfilzomib + Talquetamab-tgvs Carfilzomib + Daratumumab + Talquetamab-tgvs | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | Active, not recruiting | USA | NLD | GBR | FRA | BEL | AUS | 0 |